Geoff Ledgerwood, MD
Urology · Parker, CONPI 1962600452
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Astellas Pharma US Inc at 59.2% of the total. Reporting peaked in 2019 at $11,676 and has fallen 91.3% since, to $1,011 in 2025.
Across 160 payments — averaging $122.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$12K
- Intuitive Surgical$2K
- Medtronic$2K
- Teleflex LLC$651
- Procept Biorobotics Corporation$453
- Covidien LP$355
- plus $2K from 36 others
What the payments were for
- Consulting fees$2,37512%
- Speaking & faculty fees$10,57554%
- Travel & lodging$1,2316%
- Food & beverage$4,88125%
- Education$4862%
- Gifts$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 29 | $11,589 |
| Intuitive Surgical | 21 | $2,216 |
| Medtronic | 3 | $2,045 |
| Teleflex LLC | 4 | $651 |
| Procept Biorobotics Corporation | 4 | $453 |
| Covidien LP | 1 | $355 |
| Boston Scientific | 10 | $349 |
| AbbVie(2 entities) | 13 | $209 |
| Coloplast | 3 | $168 |
| Johnson & Johnson | 3 | $144 |
| Axonics, Inc. | 4 | $123 |
| Olympus America Inc. | 4 | $114 |
| Dendreon Pharmaceuticals LLC | 3 | $102 |
| Rochester Medical Corporation | 5 | $98 |
| Pfizer | 5 | $94 |
| Blue Earth Diagnostics | 5 | $91 |
| Ferring Pharmaceuticals Inc. | 6 | $90 |
| Bayer | 2 | $76 |
| Sumitomo Pharma America, Inc. | 3 | $72 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $69 |
| Antares Pharma, Inc. | 4 | $63 |
| BD | 2 | $35 |
| Merck | 2 | $34 |
| Aytu Biopharma, Inc. | 2 | $28 |
| Novartis | 1 | $26 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $25 |
| 180 Medical, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Dentsply IH Inc. | 1 | $19 |
| Convatec Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Accord Healthcare, Inc. | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Agiliti Surgical, Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Neotract Inc. | 1 | $14 |
| Urogen Pharma, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$10,825
- Da Vinci Surgical System$1,232
- DA VINCI SP$564
- AQUABEAM SYSTEM$270
- AquaBeam Robotic System$165
- RESTORELLE$125
- SpaceOAR VUE System - 10mL$119
- XTANDI$118
How this compares
$19,584 in reported general payments places this provider in the 85th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 53 | $58,204 |
| OrgovyxRelugolix | 12 | $30,328 |
| Tamsulosin Hcl | 385 | $4,147 |
| Testosterone Cypionate | 52 | $1,971 |
| Estradiol | 24 | $1,482 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $1,058 |
| Finasteride | 90 | $896 |
| Solifenacin Succinate | 17 | $675 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $656 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $264 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $186 |
| Ciprofloxacin Hcl | 18 | $138 |
| Terazosin Hcl | 11 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $11,589 | $58,20453 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $72 | $30,32812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 urology providers in Colorado.
Other urology in Parker
- Damian SorceParker$224K
- Nancy HuffParker$16K
- Lawrence KarshDenver$706K
- Alexandra RogersLafayette$476K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.